drugset / Trial / NCT07044401

A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices

NCT07044401

Phase 1 Completed 51 enrolled Kailera
RandomizedCrossoverOpen-labelBasic science

Summary

The main objective of the study is to assess the relative bioavailability of KAI-9531 subcutaneous (SC) injection in the upper arm and thigh compared to the abdomen.

Timeline

Start
2025-07-14
Primary completion
2025-11-13
Completion
2025-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject KAI-9531 Unknown Subcutaneous

Indications

No indication recorded.